Journal of Shandong University (Health Sciences) ›› 2023, Vol. 61 ›› Issue (11): 82-88.doi: 10.6040/j.issn.1671-7554.0.2023.0510

Previous Articles    

SMARCA2-deficient undifferentiated bowel cancer: a report of 4 cases and literature review

LI Zhe1, ZHANG Zhenkun2, ZHANG Shukun3   

  1. 1. Weifang Medical University, Weifang 261053, Shandong, China;
    2. Department of Oncology, Shouguang Peoples Hospital, Weifang 262700, Shandong, China;
    3. Department of Pathology, Weihai Municipal Hospital, Weihai 264200, Shandong, China
  • Published:2023-12-12

PDF (PC)

144

Abstract: Objective To explore the clinicopathological features of SMARCA2-deficient undifferentiated bowel cancer. Methods Clinical data of patients with undifferentiated bowel cancer and negative SMARCA2 expression diagnosed in Weihai Municipal Hospital during Jan. 2016 and Dec. 2020 were collected. The sections of HE staining were re-examined, the histological morphology was re-observed, and the undifferentiated morphology was re-determined by senior pathologists. The representative sections extracted from paraffin-embedded formalin-fixed tissue blocks were stained with automatic immunohistochemical staining machine. Results All four patients died within 1 year. HE staining showed highly malignant morphology. Conclusion SMARCA2 depletion is an indicator of poor prognosis and may be involved in tumor dedifferentiati

Key words: SWI/SNF complex, SMARCA2 depletion, Undifferentiation, Bowel cancer, Clinicopathological features

CLC Number: 

  • R365
[1] Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2): 182-188.
[2] Peterson CL, Dingwall A, Scott MP. Five SWI/SNF gene products are components of a large multisubunit complex required for transcriptional enhancement[J]. Proc Natl Acad Sci U S A, 1994, 91(8): 2905-2908.
[3] Centore RC, Sandoval GJ, Soares LMM, et al. Mammalian SWI/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies[J]. Trends Genet, 2020, 36(12): 936-950.
[4] Masliah-Planchon J, Bièche I, Guinebretière JM, et al. SWI/SNF chromatin remodeling and human malignancies[J]. Annu Rev Pathol, 2015, 10: 145-171.
[5] Raab JR, Runge JS, Spear CC, et al. Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits[J]. Epigenetics Chromatin, 2017, 10(1): 62.
[6] Marquez-Vilendrer SB, Rai SK, Gramling SJ, et al. Loss of the SWI/SNF ATPase subunits BRM and BRG1 drives lung cancer development[J]. Oncoscience, 2016, 3(11/12): 322-336.
[7] Bultman S, Gebuhr T, Yee D, et al. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes[J]. Mol Cell, 2000, 6(6): 1287-1295.
[8] Reyes JC, Barra J, Muchardt C, et al. Altered control of cellular proliferation in the absence of mammalian Brahma(SNF2alpha)[J]. EMBO J, 1998, 17(23): 6979-6991.
[9] Coisy-Quivy M, Disson O, Roure V, et al. Role for Brm in cell growth control[J]. Cancer Res, 2006, 66(10): 5069-5076.
[10] Villatoro TM, Ma CQ, Pai RK. Switch/sucrose nonfermenting nucleosome complex-deficient colorectal carcinomas have distinct clinicopathologic features[J]. Hum Pathol, 2020, 99: 53-61.
[11] Cohet N, Stewart KM, Mudhasani R, et al. SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells[J]. J Cell Physiol, 2010, 223(3): 667-678.
[12] Kobayashi H, Kawahara N, Ogawa K, et al. Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary[J]. Biomed Rep, 2018, 9(2): 112-118.
[13] Yang M, Sun Y, Ma L, et al. Complex alternative splicing of the smarca2 gene suggests the importance of smarca2-B variants[J]. J Cancer, 2011, 2: 386-400.
[14] Huang SC, Ng KF, Chang IY, et al. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes[J]. PLoS One, 2021, 16(1): e0245356. doi:10.1371/journal.pone.0245356.
[15] Jancewicz I, Siedlecki JA, Sarnowski TJ, et al. BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?[J]. Epigenetics Chromatin, 2019, 12(1): 68.
[16] SUN S, LI Q, ZHANG Z, et al. SMARCA2 deficiency in NSCLC: a clinicopathologic and immunohistochemical analysis of a large series from a single institution [J]. Environ Health Prev Med, 2022, 27: 3. doi: 10.1265/ehpm.21-00254.
[17] Glaros S, Cirrincione GM, Muchardt C, et al. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy[J]. Oncogene, 2007, 26(49): 7058-7066.
[18] Kahali B, Gramling SJ, Marquez SB, et al. Identifying targets for the restoration and reactivation of BRM[J]. Oncogene, 2014, 33(5): 653-664.
[19] Bourachot B, Yaniv M, Muchardt C. Growth inhibition by the mammalian SWI-SNF subunit Brm is regulated by acetylation[J]. EMBO J, 2003, 22(24): 6505-6515.
[20] Kahali B, Yu JL, Marquez SB, et al. The silencing of the SWI/SNF subunit and anticancer gene BRM in rhabdoid tumors[J]. Oncotarget, 2014, 5(10): 3316-3332.
[21] Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation[J]. Nat Rev Drug Discov, 2014, 13(5): 337-356.
[22] Shorstova T, Marques M, Su J, et al. SWI/SNF-compromised cancers are susceptible to bromodomain inhibitors[J]. Cancer Res, 2019, 79(10): 2761-2774.
[23] McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations[J]. Nature, 2012, 492(7427): 108-112.
[24] Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2[J]. Proc Natl Acad Sci U S A, 2013, 110(19): 7922-7927.
[25] Kawano S, Grassian AR, Tsuda M, et al. Preclinical evidence of anti-tumor activity induced by EZH2 inhibition in human models of synovial sarcoma[J]. PLoS One, 2016, 11(7): e0158888. doi:10.1371/journal.pone.0158888.
[26] Song XJ, Zhang LD, Gao TT, et al. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation[J]. Biomedecine Pharmacother, 2016, 81: 288-294.
[27] Januario T, Ye XF, Bainer R, et al. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors[J]. Proc Natl Acad Sci U S A, 2017, 114(46): 12249-12254.
[28] Chan-Penebre E, Armstrong K, Drew A, et al. Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: in vitro and in vivo preclinical models[J]. Mol Cancer Ther, 2017, 16(5): 850-860.
[29] Wang NY, Qin Y, Du FR, et al. Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Gene, 2022, 834: 146638. doi:10.1016/j.gene.2022.146638.
[30] Jancewicz I, Szarkowska J, Konopinski R, et al. PD-L1 overexpression, SWI/SNF complex deregulation, and profound transcriptomic changes characterize cancer-dependent exhaustion of persistently activated CD4+ T cells[J]. Cancers, 2021, 13(16): 4148.
[1] MU Yanxi, WANG Wenjie, CHEN Kang, YAO Yalong, LI Jinzhou, WEI Haoqi, LIU Haipeng, HUANG Zeping, CHEN Xiao. Exploring the clinicopathological features of three cases of gastric cancer in one pedigree during short-term [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 96-101.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd